Biobehavioral-Cytokine Interactions in Ovarian Cancer
NCT01113112 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 613
Last updated 2026-02-06
Summary
The purpose of this study is to understand relationships between behavioral factors, hormones, and chemicals produced by the body that may help tumor growth in ovarian cancer.
Conditions
- Ovarian Neoplasms
Sponsors & Collaborators
-
University of Iowa
collaborator OTHER -
National Cancer Institute (NCI)
collaborator NIH -
Washington University School of Medicine
collaborator OTHER -
Susan Lutgendorf
lead OTHER
Principal Investigators
-
Susan Lutgendorf, Ph.D. · University of Iowa
-
Premal Thaker, MD · Washington University School of Medicine
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-08-31
- Primary Completion
- 2015-11-10
- Completion
- 2026-01-02
Countries
- United States
Study Locations
More Related Trials
-
Appraising Medical Trial Experiences of Ovarian Cancer Patients
NCT05801796 ·Status: NOT_YET_RECRUITING
-
Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab
NCT01706120 ·Status: UNKNOWN ·Phase: PHASE4
-
Cancer Loyalty Card Study
NCT03994653 ·Status: COMPLETED
-
Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer
NCT02399592 ·Status: COMPLETED ·Phase: PHASE2
-
Risk of Ovarian Cancer in Patients With a Pelvic Mass
NCT00315692 ·Status: COMPLETED
-
Ovarian Tumor Biopsies to Study Response to Treatments
NCT02952521 ·Status: COMPLETED
-
Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer
NCT06019923 ·Status: RECRUITING
-
Quality-of-Life Study of Patients With Previously Treated Ovarian Cancer
NCT00003794 ·Status: TERMINATED
-
Study of Genes and the Environment in Patients With Ovarian Cancer in the East Anglia, Oxford, Trent, or West Midlands Regions of the United Kingdom
NCT00757263 ·Status: UNKNOWN
-
Dysregulation of Whole-body Metabolism in Ovarian Cancer: A Longitudinal Study
NCT06800105 ·Status: RECRUITING
-
A Multicenter Trial On The Utility and Impact Of Computed Tomography and Serum CA-125 In the Management of Newly Diagnosed Ovarian Cancer
NCT00587093 ·Status: COMPLETED ·Phase: NA
-
Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00079430 ·Status: COMPLETED ·Phase: PHASE1
-
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
NCT01468909 ·Status: COMPLETED ·Phase: PHASE2
-
Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT01295489 ·Status: COMPLETED
-
A Prospective Multicenter Diagnostic Biomarker Study to Discriminate Borderline From Stage I Invasive Ovarian Cancer
NCT06709872 ·Status: RECRUITING
-
Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer
NCT00511992 ·Status: COMPLETED ·Phase: PHASE2
-
Depression and Interleukin-6 Production in Patients With Ovarian Epithelial Cancer
NCT00460200 ·Status: WITHDRAWN
-
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
NCT00085358 ·Status: COMPLETED ·Phase: PHASE1
-
DOD Long-Term Survivors of Ovarian Cancer
NCT02321735 ·Status: UNKNOWN ·Phase: NA
-
Chemotherapy-Related Toxicities In Ovarian Cancer Patients
NCT00508378 ·Status: COMPLETED
-
Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary
NCT00626873 ·Status: COMPLETED ·Phase: PHASE1
-
Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
NCT01080521 ·Status: COMPLETED
-
Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass
NCT00238342 ·Status: UNKNOWN ·Phase: NA
-
Oxford Ovarian Cancer Predict Chemotherapy Response 01
NCT01770535 ·Status: UNKNOWN
-
Improving Quality of Care for Patients With Recurrent Ovarian Cancer
NCT02809339 ·Status: UNKNOWN